Leerink initiated coverage of Contineum (CTNM) with an Outperform rating and $20 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b Results
- Buy Rating for Contineum Therapeutics’ PIPE-791: Promising Phase 1b Results and Competitive Edge
- Contineum announces topline data from PIPE-791 trial
- Contineum Therapeutics Announces Positive Phase 1b Trial Results
- 3 Best Stocks to Buy Now, 8/19/2025, According to Top Analysts